News & Updates

For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.

Full vaccination (two doses) with an mRNA COVID-19 vaccine during pregnancy was associated with a reduced risk of COVID-19-related hospitalization among infants younger than 6 months of age, according to a recent study.

The risk of myopericarditis after COVID-19 vaccination is not greater than that following other non–COVID-19 vaccinations, according to a systematic review and meta-analysis conducted by researchers in Singapore.

In the treatment and prevention of recurrent yeast infection or vulvovaginal candidiasis, oteseconazole performs similarly to standard-of-care fluconazole but better as compared with placebo, as shown in the results of the phase III ultraviolet study.

Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.

The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.

For male patients with inflammatory bowel disease (IBD), treatment with biologic, thiopurine, or methotrexate does not appear to promote impairments in fertility or adverse pregnancy outcomes, according to a study.

COVID-19 vaccination-induced uveitis is uncommon, with cases mostly self-limiting and showing good responses to treatment with no long-term sequelae, according to a Singapore study. However, reactivation of such infections appears to occur at a higher proportion in Southeast Asia, where viral and toxoplasma infections are more common.

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.